Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leg artery study halted: did platelet screening help?

NCT ID NCT04007055

Disease control Sponsor: Marissa Jarosinski Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looked at whether screening people for high platelet reactivity (a condition where blood clots easily) before leg artery procedures could improve outcomes. It involved 31 adults with peripheral artery disease who were scheduled for angioplasty or stenting. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

31 people

The number who actually took part.

Started

Aug 2019

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Peripheral arterial disease * Planned angioplasty or stenting of superficial femoral artery or popliteal artery. Exclusion Criteria: * Patients treated on an emergency basis * Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty) * Planned intervention at site exclusive of superficial femoral artery or popliteal artery * Planned re-stenting at site of prior stent placement * Planned re-angioplasty at site of prior angioplasty * Known inability to tolerate antiplatelet regimen before enrollment * Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center * Current use of prasugrel or ticlopidine * Current use of oral anticoagulation medication * Pregnant patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arterial disorder peripheral arterial disease peripheral arterial occlusive disease 1 peripheral vascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artery disease Clopidogrel, poor metabolism of Peripheral arterial occlusive disease Peripheral artery disease Peripheral vascular disease

Contacts and locations

Locations

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.